Liver diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Other liver diseases including cirrhosis and chronic hepatitis are related with an increased level of AFP.
|
19968979 |
2010 |
Liver diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We performed RT-PCR to detect the expression of hTERT mRNA in 78 patients with HCC, 10 with liver cirrhosis (LC), 12 with chronic hepatitis (CH), and 34 healthy individuals without any liver diseases and cancers, and statistically analyzed the association with clinical parameters which include age, sex, etiology, Child classification, underlying liver disease, biochemical data, alpha-fetoprotein (alpha-AFP) number and size of tumor, and histological differentiation of HCC regarding HCC patients.
|
12759542 |
2003 |
Liver diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Child-Pugh A liver disease (B vs. A) (HR 1.45 95% CI 1.17-1.79, p < 0.001; I<sup>2</sup> = 0%, p = 0.49) and AFP levels (> 400 vs. ≤ 400 ng/ml) (HR 1.36 95% CI 1.09-1.71, p = 0.007; I<sup>2</sup> = 90%, p = 0.001) were associated with improved OS.
|
30073454 |
2018 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Surveillance of children with chronic liver diseases with ultrasound and alpha-fetoprotein may be helpful in timely detection, intervention and overall improvement in outcome of HCC.
|
30254403 |
2018 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Compared to each biomarker alone, the combination of AFP and PIVKA-II with age and gender improved the accuracy of detecting HCC and differentiating HCC from non-malignant liver disease.
|
30675135 |
2019 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, in two-thirds of hepatoma patients the AFP profile was different from the profile observed in patients with benign liver disorders.
|
6171874 |
1981 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Serum levels of liver enzymes, such as alanine transaminase, aspartate transaminase, and α-fetoprotein, provide insight into liver function and are used during treatment of liver disease, but such information is limited.
|
26927063 |
2016 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-fetoprotein elevation has been associated with chronic liver diseases and a limited number of cancers.
|
28407756 |
2017 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Central venous blood of patients with HCC (n = 24) and patients with benign liver diseases (n = 13) equally demonstrated AFP-expressing cells.
|
10668884 |
2000 |
Liver diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
AFP-positive and AFP-negative carcinomas occurred in the same liver.
|
16965562 |
2006 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study aims to detect the sensitivity of the new biomarker miR-212 existing in serum exosomes along with other hepatocellular carcinoma biomarkers such as AFP (alpha-fetoprotein), CA125 (carbohydrate antigen-ca125), and Hbx protein in the diagnosis of HBV-related liver diseases.
|
31608838 |
2019 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
AFP could still be a reliable tool in diagnosis and prognosis of HCC patients especially in developing countries due to its relevant association with aspects of advanced tumor and liver disease, gender and a poor functional status.
|
31263843 |
2019 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients.
|
23319432 |
2013 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, the combination of serum miR-182, miR-331-3p, and alpha-fetoprotein (AFP) can markedly increase the differential diagnostic value of benign and malignant liver diseases, especially better than serum AFP alone, P < 0.05.
|
25903466 |
2015 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
However, it has been indicated that AFP-L3 and DCP excel AFP in differentiating hepatocellular carcinoma from nonmalignant hepatopathy and detecting small hepatocellular carcinoma.
|
16534867 |
2006 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Collagen IV, hyaluronic acid, platelet-derived growth factor (PDGF) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured by ELISA, and AST, ALT, platelet count, albumin, total bilirubin, INR and AFP by routine methods in 148 patients with hepatitis C induced liver disease.
|
28945150 |
2018 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
There was a significant interaction between AFP category and etiology of liver disease (P < 0.001).
|
30362249 |
2019 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data indicate that the combination of AFP and NLR offers better diagnostic performance than either marker alone for differentiating HCC from liver disease, which may benefit clinical screening.
|
30545306 |
2018 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-fetoprotein (AFP) has been shown to predict the prognosis of liver disease in several studies.
|
29300103 |
2018 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, the combination of dual serum fluorescence, AFP, hepatic function tests and age is simple and valuable for identifying HCC in serum AFP-elevated liver diseases.
|
29228649 |
2017 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Circulating HMGB3 levels were quantitatively detected in a cohort of 225 patients with chronic liver diseases by ELISA and compared with alpha-fetoprotein by the receiver operating characteristic curve.
|
30538547 |
2018 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
DCV-TRIO administered for 12 weeks to Japanese patients with primarily GT-1b infection achieved a high SVR12 rate and resulted in improved measures of hepatic fibrosis and serum AFP that may reduce the risk of future liver disease progression and hepatocellular carcinoma, particularly in those with compensated cirrhosis.
|
29500489 |
2018 |
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
The aim of this study was to evaluate the ability of inflammatory correction-based AFP to identify HCC from other liver diseases.From March 2012 to March 2017, among 926 participants, a total of 501 patients whose transaminases were higher than the upper limit of normal range, including 166 treatment-naïve HCC patients were enrolled in our retrospective study.
|
31027143 |
2019 |
Liver diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Seventy-nine patients had NTM-RFA and 62 had SR. After IPTW, the two groups were well-balanced for most baseline characteristics including tumor size, location, etiology, severity of underlying liver disease and alpha-fetoprotein level.
|
29410287 |
2018 |
Liver diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although the level of AFP is increased in HCC, its sensitivity for diagnosis is poor because AFP levels are also increased in liver diseases.
|
29888876 |
2018 |